bluebird bio: Positive Resolution Of Clinical Hold Could Drive Asymmetrical Upside
TipRanks via Yahoo Finance· 4 days agoThe challenge facing BLUE is how to resolve the issues it encountered with one of its first patients...
Agios' (AGIO) Q4 Loss In Line, Revenues Surpass Estimates
Zacks via Yahoo Finance· 1 day agoAgios Pharmaceuticals, Inc. AGIO reported fourth-quarter 2020 loss of $1.41 per share, which was in...
Magenta Is Ready to Paint Your Portfolio Green
Motley Fool· 5 hours agoFor patients with certain blood cancers, a stem cell transplant can often be a curative treatment. Enter Magenta Therapeutics (NASDAQ: MGTA). The...
15 Fastest Growing Biotech Companies in the US
Insider Monkey via Yahoo Finance· 4 hours agoHeadquarters: San Diego, CA No. of employees: 310 Revenue (2018): $21.2 million Revenue (2019): $31.43 million Founded in 2006, Sorrento Therapeutics,...
Intellia (NTLA) Miss Earnings & Revenues Estimates in Q4
Zacks via Yahoo Finance· 2 days agoIntellia Therapeutics, Inc. NTLA is a clinical-stage company with focus on developing gene editing...
Kura Oncology, Inc. (KURA) Q4 2020 Earnings Call Transcript
Motley Fool· 3 days agoLadies and gentlemen, thank you for standing by and welcome to the Kura Oncology Fourth Quarter and...
Is There Any Hope for bluebird bio Stock?
Motley Fool· 3 days agoThe share price of bluebird bio (NASDAQ: BLUE) is down a staggering 70% over the past year. The company has encountered more roadblocks than expected on...
FATE Reports Wider-Than-Expected Q4 Loss on Higher Expenses
Zacks via Yahoo Finance· 2 days agoFate Therapeutics FATE reported a loss of 61 cents per share in the fourth quarter of 2020, wider...
Recap: Jazz Pharmaceuticals Q4 Earnings
Benzinga via Yahoo Finance· 4 days agoShares of Jazz Pharmaceuticals (NASDAQ:JAZZ) were flat in after-market trading after the company reported Q4 results. Earnings per share decreased 9.50% year over year to $4.00, which missed ...